Semuloparin sodium
Clinical data | |
---|---|
ATC code | None |
Legal status | |
Legal status |
|
Identifiers | |
Synonyms | AVE-5026 |
CAS Number | 9041-08-1 |
ChemSpider | none |
UNII | V5T10N50RD |
ECHA InfoCard | 100.110.590 |
Chemical and physical data | |
Molar mass | 2000–3000 g/mol (average) |
Semuloparin (INN, USAN) is an experimental antithrombotic being developed by Sanofi-Aventis and belongs to the group of low molecular weight heparins (LMWH).[1] It has completed Phase III clinical trials for the prevention of thromboembolism following various kinds of surgery such as hip replacement,[2] as well as for patients undergoing chemotherapy.[3]
Like bemiparin, semuloparin is classified as an ultra-LMWH because of its low molecular mass of 2000–3000 g/mol on average. (Enoxaparin has 4500 g/mol) These heparins have lower anti-thrombin activity than classical LMWHs and act mainly on factor Xa, reducing the risk of bleeding.[4][5]
References
- ↑ Gomez-Outes, A.; Suarez-Gea, M. L.; Lecumberri, R.; Rocha, E.; Pozo-Hernandez, C.; Vargas-Castrillon, E. (2010). "New parenteral anticoagulants in development". Therapeutic Advances in Cardiovascular Disease. 5 (1): 33–59. doi:10.1177/1753944710387808. PMID 21045018.
- ↑ Clinical trial number NCT00697099 for "Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery (SAVE-HIP1)" at ClinicalTrials.gov
- ↑ Clinical trial number NCT00694382 for "Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy (SAVE-ONCO)" at ClinicalTrials.gov
- ↑ Jeske, W. P.; Hoppensteadt, D.; Gray, A.; Walenga, J. M.; Cunanan, J.; Myers, L.; Fareed, J.; Bayol, A.; Rigal, H. L. N.; Viskov, C. (2011). "A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin". Thrombosis Research. 128 (4): 361–367. doi:10.1016/j.thromres.2011.03.001. PMID 21458847.
- ↑ Statement On A Nonproprietary Name Adopted By The Usan Council: Semuloparin Sodium
This article is issued from Wikipedia - version of the 6/7/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.